# Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy

> **NCT02723448** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 4 (actual)

## Conditions studied

- Vasculopathy, Retinal, With Cerebral Leukodystrophy
- Cerebroretinal Vasculopathy, Hereditary

## Interventions

- **DRUG:** aclarubicin

## Key facts

- **NCT ID:** NCT02723448
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2020-07-23
- **Final completion:** 2020-07-23
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723448, "Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02723448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*